CA3059447A1 - Anti-pd-l1 antibody and use thereof - Google Patents
Anti-pd-l1 antibody and use thereof Download PDFInfo
- Publication number
- CA3059447A1 CA3059447A1 CA3059447A CA3059447A CA3059447A1 CA 3059447 A1 CA3059447 A1 CA 3059447A1 CA 3059447 A CA3059447 A CA 3059447A CA 3059447 A CA3059447 A CA 3059447A CA 3059447 A1 CA3059447 A1 CA 3059447A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- heavy chain
- cancer
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2017/028206 | 2017-04-18 | ||
| US2017028206 | 2017-04-18 | ||
| PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059447A1 true CA3059447A1 (en) | 2018-10-25 |
Family
ID=63856823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059447A Pending CA3059447A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (enExample) |
| EP (1) | EP3612565A4 (enExample) |
| JP (2) | JP2020517239A (enExample) |
| KR (1) | KR102323960B1 (enExample) |
| CN (1) | CN110856446A (enExample) |
| AU (1) | AU2018256392B2 (enExample) |
| BR (1) | BR112019021828B1 (enExample) |
| CA (1) | CA3059447A1 (enExample) |
| CL (1) | CL2019002953A1 (enExample) |
| CO (1) | CO2019012118A2 (enExample) |
| EA (1) | EA201900443A1 (enExample) |
| MA (1) | MA50038A (enExample) |
| MX (1) | MX2019012461A (enExample) |
| MY (1) | MY199319A (enExample) |
| PH (1) | PH12019502302A1 (enExample) |
| SG (1) | SG11201909041SA (enExample) |
| WO (1) | WO2018195226A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| JP7695881B2 (ja) * | 2018-11-14 | 2025-06-19 | アイバイオ， インク． | 操作されたｃｄ２５ポリペプチドおよびその使用 |
| JP7619941B2 (ja) | 2018-11-14 | 2025-01-22 | アイバイオ， インク． | Ｃｄ２５抗体 |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| AU2020271467B2 (en) * | 2019-04-11 | 2024-06-27 | Scripps Korea Antibody Institute | Antibodies against programmed death-ligand 1 and uses thereof |
| BR112021005365A2 (pt) * | 2019-04-26 | 2021-11-16 | I Mab Biopharma Us Ltd | Anticorpo ou fragmento de ligação ao antígeno do mesmo, anticorpo biespecífico, composição, um ou mais polinucleotídeos, célula isolada, método para tratar câncer ou infecção, e, uso do anticorpo ou fragmento do mesmo ou da composição |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| WO2022031695A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
| TW202317640A (zh) * | 2021-09-24 | 2023-05-01 | 大陸商廣東菲鵬製藥股份有限公司 | 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| HRP20170908T1 (hr) * | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| US10835595B2 (en) * | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| CA2940242A1 (en) * | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CA2978942A1 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| JP7011657B2 (ja) * | 2016-10-30 | 2022-02-10 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｐｄ－ｌ１抗体および変異型 |
-
2018
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active Active
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt active IP Right Grant
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en active Pending
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018195226A1 (en) | 2018-10-25 |
| EP3612565A4 (en) | 2021-06-16 |
| CO2019012118A2 (es) | 2020-04-01 |
| JP2020517239A (ja) | 2020-06-18 |
| JP2023025003A (ja) | 2023-02-21 |
| BR112019021828B1 (pt) | 2022-09-20 |
| PH12019502302A1 (en) | 2020-09-21 |
| MA50038A (fr) | 2020-07-08 |
| EA201900443A1 (ru) | 2020-03-06 |
| EP3612565A1 (en) | 2020-02-26 |
| CL2019002953A1 (es) | 2020-01-10 |
| AU2018256392A1 (en) | 2019-10-17 |
| KR20190141169A (ko) | 2019-12-23 |
| BR112019021828A2 (pt) | 2020-03-24 |
| MY199319A (en) | 2023-10-24 |
| SG11201909041SA (en) | 2019-11-28 |
| CN110856446A (zh) | 2020-02-28 |
| US20210115143A1 (en) | 2021-04-22 |
| AU2018256392B2 (en) | 2024-05-16 |
| MX2019012461A (es) | 2019-12-11 |
| KR102323960B1 (ko) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018256392B2 (en) | Anti-PD-L1 antibody and use thereof | |
| TWI772586B (zh) | 三鏈抗體、其製備方法及其用途 | |
| US12325742B2 (en) | Anti-mesothelin antibodies | |
| US11746148B2 (en) | Antibody molecules comprising a single-domain antigen-binding site and Fab fragments | |
| US11008391B2 (en) | Anti-PD-1 antibodies | |
| US12497455B2 (en) | Anti-CD3E/BCMA bispecific antibody and use thereof | |
| TWI844684B (zh) | 一種抗ceacam5的單殖株抗體及其製備方法和用途 | |
| JP2021524268A (ja) | Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子 | |
| JP2020535839A (ja) | Ｃｄ４７およびｐｄ−ｌ１に特異的な抗体 | |
| CN105777906A (zh) | 抗pd-l1全人抗体及其应用 | |
| RS64977B1 (sr) | Nova anti-pd-l1 antitela | |
| JP2021533204A (ja) | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 | |
| JP7457822B2 (ja) | 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用 | |
| TW202200615A (zh) | 用於治療和預防患者的crs之方法 | |
| CA3228137A1 (en) | Cldn18.2-targeting antibody, bispecific antibody and use thereof | |
| WO2022224997A1 (ja) | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 | |
| TWI833227B (zh) | 靶向pd-l1和cd73的特異性結合蛋白及其應用 | |
| TWI835166B (zh) | 靶向pd-1和/或ox40的特異性結合蛋白及其應用 | |
| US12509520B2 (en) | Anti-CD3 and anti-CD123 bispecific antibody and use thereof | |
| US20250289901A1 (en) | Anti-cd3e/bcma bispecific antibody and use thereof | |
| EA044327B1 (ru) | Антитело к pd-l1 и его применение | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
| TW202438528A (zh) | 特異性結合Ｃｌａｕｄｉｎ １８．２的抗體及其製法和應用 | |
| WO2025113640A1 (zh) | 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途 | |
| CN115466329A (zh) | 一种抗pd-1人源化抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230728 |
|
| EEER | Examination request |
Effective date: 20230728 |